These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 9531875)

  • 41. Hemodynamic changes induced by urinary human chorionic gonadotropin and recombinant luteinizing hormone used for inducing final follicular maturation and luteinization.
    Manau D; Fábregues F; Arroyo V; Jiménez W; Vanrell JA; Balasch J
    Fertil Steril; 2002 Dec; 78(6):1261-7. PubMed ID: 12477522
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recombinant human follicle-stimulating hormone stimulates multiple follicular growth, but minimal estrogen production in gonadotropin-releasing hormone antagonist-treated monkeys: examining the role of luteinizing hormone in follicular development and steroidogenesis.
    Karnitis VJ; Townson DH; Friedman CI; Danforth DR
    J Clin Endocrinol Metab; 1994 Jul; 79(1):91-7. PubMed ID: 8027261
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. I. Comparison of an FSH-dominant and a purified FSH preparation.
    Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
    Int J Fertil Womens Med; 1997; 42(5):306-10. PubMed ID: 9406836
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral contraceptive pills and follicular fluid hormones in an in vitro fertilization program.
    Weisman Z; Dirnfeld M; Lissak A; Sorokin Y; Abramovici H
    Fertil Steril; 1989 Sep; 52(3):451-3. PubMed ID: 2506078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women.
    Laml T; Obruca A; Fischl F; Huber JC
    Gynecol Endocrinol; 1999 Apr; 13(2):98-103. PubMed ID: 10399054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum and follicular fluid hormone levels during in vitro fertilization after short- or long-course treatment with a gonadotropin-releasing hormone agonist.
    Bo-Abbas YY; Martin KA; Liberman RF; Cramer DW; Barbieri RL
    Fertil Steril; 2001 Apr; 75(4):694-9. PubMed ID: 11287021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.
    Gelety TJ; Pearlstone AC; Surrey ES
    Fertil Steril; 1995 Dec; 64(6):1074-80. PubMed ID: 7589655
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH.
    Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
    Int J Fertil Womens Med; 1997; 42(6):431-5. PubMed ID: 9459089
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simplification of the method of in vitro fertilization: sonographic measurements of follicular diameter as the sole index of follicular maturity.
    Nilsson L; Wikland M; Hamberger L; Hillensjö T; Chari S; Sturm G; Daume E
    J In Vitro Fert Embryo Transf; 1985 Mar; 2(1):17-22. PubMed ID: 3926921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Porcine follicle-stimulating hormone treatment of gilts during an altrenogest-synchronized follicular phase: effects on follicle growth, hormone secretion, ovulation, and fertilization.
    Guthrie HD; Pursel VG; Wall RJ
    J Anim Sci; 1997 Dec; 75(12):3246-54. PubMed ID: 9419999
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone.
    Balasch J; Miró F; Burzaco I; Casamitjana R; Civico S; Ballescá JL; Puerto B; Vanrell JA
    Hum Reprod; 1995 Jul; 10(7):1678-83. PubMed ID: 8582960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM; Camus M; Kolibianakis EM; Tournaye H; Papanikolaou EG; Donoso P; Devroey P
    Fertil Steril; 2007 Mar; 87(3):504-8. PubMed ID: 17140572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of LH supplementation to the GnRH antagonist protocol in advanced reproductive ageing women: a prospective randomized controlled study.
    Younis JS; Izhaki I; Ben-Ami M
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):99-106. PubMed ID: 26304041
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.
    Fleming R; Chung CC; Yates RW; Coutts JR
    Hum Reprod; 1996 Sep; 11(9):1854-8. PubMed ID: 8921053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development.
    Loumaye E; Vankrieken L; Depreester S; Psalti I; de Cooman S; Thomas K
    Fertil Steril; 1989 Jan; 51(1):105-11. PubMed ID: 2491990
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists.
    Kolibianakis EM; Albano C; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Fertil Steril; 2004 Jul; 82(1):102-7. PubMed ID: 15236997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.